Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Second-Line Treatment Options for Lower-Risk MDS

February 2nd 2023

Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.

Data on Emerging Therapies for Treatment of Higher-Risk MDS

February 1st 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

Oral Hypomethylating Agents in MDS: Data Updates

February 1st 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Taking a Closer Look at Cilta-cel and CARTITUDE-1 Data

February 1st 2023

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

Remestemcel-L BLA Resubmitted to FDA for Pediatric Steroid-Refractory aGVHD

February 1st 2023

A biologics license application seeking the approval of remestemcel-L has been resubmitted to the FDA for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin Produces Promising Efficacy in Hodgkin Lymphoma

January 31st 2023

Mitul Gandhi, MD, discusses the rationale of combining brentuximab vedotin, nivolumab, dacarbazine, and doxorubicin for patients with early-stage classic Hodgkin lymphoma, the key findings from part C of the SGN35-027 trial, and the next steps for investigating this combination.

Tumor Lysis Syndrome: Clinical Implications of Prophylaxis and Treatment

January 31st 2023

Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.

Acute Myeloid Leukemia: Optimizing Risk Stratification

January 31st 2023

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

Molecular Biomarker Testing in Acute Myeloid Leukemia

January 31st 2023

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Guideline-Directed Treatment Options for Tumor Lysis Syndrome

January 31st 2023

James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.

NICE Recommends Axicabtagene Ciloleucel for Lymphoma

January 30th 2023

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of axicabtagene ciloleucel for adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma following at least 2 previous lines of systemic therapy.

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

The combination of magrolimab, rituximab, gemcitabine, and oxaliplatin produced deep, durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of luspatercept for the treatment of patients with anemia associated with non–transfusion dependent beta thalassemia.

Steroid Refractory Acute GvHD and REACH Trials

January 27th 2023

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options

January 27th 2023

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

The FDA has granted a fast track designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome.

First-Line Treatment Options for Lower-Risk MDS

January 26th 2023

Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

Considerations for MDS Pathology and Risk Status Reporting

January 26th 2023

A focused discussion on best practices for MDS pathology and risk status reporting in both community and academic center settings.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.